(12) **Translation of European patent specification**

(11) **NO/EP 3928836 B1**

NORWAY

(19) NO

(51) Int Cl.

A61P 35/00 (2006.01)
A61K 31/506 (2006.01)
C07D 403/12 (2006.01)
C07D 403/14 (2006.01)
C07D 405/14 (2006.01)
C07D 409/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.12.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.09.18
(86)	European Application Nr.	21186831.0
(86)	European Filing Date	2016.11.17
(87)	The European Application's Publication Date	2021.12.29
(30)	Priority	2015.11.20, WO, PCT/EP15/077269
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(62)	Divided application	EP3377483, 2016.11.17
(73)	Proprietor	Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil, Sveits
(72)	Inventor	FRETZ, Heinz, 3654 Gunten, Sveits LYOTHIER, Isabelle, 4123 Allschwil, Sveits POTHIER, Julien, 4123 Allschwil, Sveits RICHARD-BILDSTEIN, Sylvia, 4123 Allschwil, Sveits SIFFERLEN, Thierry, 4123 Allschwil, Sveits WYDER PETERS, Lorenza, 81675 Munich, Tyskland POZZI, Davide, 4123 Allschwil, Sveits CORMINBOEUF, Olivier, 4123 Allschwil, Sveits
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge

(54) Title **N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS**

(56) References Cited:

EP-A1- 2 711 364
EP-A1- 2 014 657

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse for anvendelse i forebyggingen eller behandlingen av kreft; hvori forbindelsen anvendes i kombinasjon med ett eller flere kjemoterapimidler og/eller stråleterapi og/eller målrettet terapi; hvori forbindelsen er en forbindelse av formel (I)



Formel (I)

eller et farmasøytisk akseptabelt salt derav,

hvori

$(R^1)_n$ representerer én, to eller tre valgfrie substituenter på indolringen, hvori substituentene velges uavhengig fra (C_{1-3})alkyl, (C_{1-3})alkoksy, halogen, (C_{1-3})fluoralkyl, (C_{1-3})fluoralkoksy eller cyano; eller to **R^1** sammen danner en gruppe -O-CH_2-O-, og den gjenværende **R^1**, hvis til stede, representerer halogen;

R^2 representerer (C_{1-4})alkyl, halogen eller cyano;

R^3 representerer hydrogen, metyl eller trifluormetyl;

R^{4a} og **R^{4b}** uavhengig representerer hydrogen, metyl eller **R^{4a}** og **R^{4b}** sammen med karbonatomet som de er festet til representerer en sykloprop-1,1-diylgruppe;

R^{5a} og **R^{5b}** uavhengig representerer hydrogen, metyl eller **R^{5a}** og **R^{5b}** sammen med karbonatomet som de er festet til representerer en sykloprop-1,1-diylgruppe;

Ar^1 representerer

• fenyl, eller 5- eller 6-leddet heteroaryl; hvori fenylet eller det 5- eller 6-leddede heteroarylet uavhengig er mono-, di- eller trisubstituert, hvori substituentene velges uavhengig fra

• (C_{1-6})alkyl;

• (C_{1-4})alkoksy;

• (C_{1-3})fluoralkyl, hvori (C_{1-3})fluoralkylet eventuelt substitueres med hydroksy;

• (C_{1-3})fluoralkoksy;

• halogen;

• cyano;

• (C_{3-6})sykloalkyl, hvori (C_{3-6})sykloalkylet er usubstituert eller monosubstituert med amino;

• (C_{4-6})sykloalkyl som inneholder et ringoksygenatom, hvori (C_{4-6})sykloalkylet som inneholder et ringoksygenatom er usubstituert eller monosubstituert med fluor, hydroksy eller metoksy;

• (C_{3-6})sykloalkyl-oksy;

• hydroksy;

• nitro;

• $-B(OH)_2$;

• 2,2,2-trifluor-1,1-dihydroksy-etyl;

• $-\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, hvori

▪ $\mathbf{X^1}$ representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C≡C-, -NH-CO-*, -CO- eller (C_{3-5})sykloalkylen; hvori asteriskene indikerer bindingen som er koblet til -CO-$\mathbf{R^{O1}}$-gruppen; og

▪ $\mathbf{R^{O1}}$ representerer

• -OH;

• -O-(C_{1-4})alkyl;

• -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;

• -O-fenyl;

• -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy, eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$;

• -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

• -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller

• (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

• -CO-CH_2-CN;

• -CO-CH_2-OH;

• -CO-H;

•



;

•



;

• 2-hydroksy-3,4-diokso-syklobut-1-enyl;

• hydroksy-(C_{1-4})alkyl;

• dihydroksy-(C_{2-4})alkyl;

• hydroksy-(C_{2-4})alkoksy;

• (C_{1-4})alkoksy-(C_{2-4})alkoksy;

• -(CH_2)$_m$-N$\mathbf{R^{N1}R^{N2}}$, hvori **m** representerer heltallet 0 eller 1; og hvori

▪ $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, (C_{1-4})alkoksy-(C_{2-4})alkyl, (C_{3-6})sykloalkyl, (C_{2-3})fluoralkyl, -eller -SO_2-(C_{1-4})alkyl;

▪ eller $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl, og $\mathbf{R^{N2}}$ uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl, -CO-(C_{1-3})alkylen-OH eller -CO-O-(C_{1-3})alkyl;

▪ eller $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ sammen med nitrogenet som de er festet til danner en 4-, 5- eller 6-leddet mettet ring som eventuelt inneholder ett ringoksygen- eller ringsvovelatom, hvori ringen er usubstituert, eller monosubstituert med okso på et ringkarbonatom, eller disubstituert med okso på et ringsvovelatom;

• -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy, hydroksy-(C_{2-4})alkoksy, benzyloksy eller hydroksy;

• -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

• -SO_2-$\mathbf{R^{S1}}$ hvori $\mathbf{R^{S1}}$ representerer hydroksy, (C_{1-4})alkyl eller -N$\mathbf{R^{N7}R^{N8}}$ hvori $\mathbf{R^{N7}}$ og $\mathbf{R^{N8}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl eller 2-fluor-vinyl;

• 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

• fenyl-oksy, hvori fenylet eventuelt er monosubstituert med halogen;

• benzooksazol-2-yl; eller

• -(CH_2)$_p$-**HET**, hvori **p** representerer heltallet 0 eller 1; og hvori **HET** representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede

heteroarylet er usubstituert, eller mono- eller disubstituert, hvori substituentene velges uavhengig fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• eller $\mathbf{Ar^1}$ representerer 8- til 10-leddet bisyklisk heteroaryl; hvori det 8- til 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono-, di- eller trisubstituert, hvori substituentene velges uavhengig fra (C_{1-4})alkyl; (C_{1-4})alkoksy; (C_{1-3})fluoralkyl; (C_{1-3})fluoralkoksy; halogen; cyano; hydroksy eller -(C_{0-3})alkylen-COO$\mathbf{R^{O2}}$ hvori $\mathbf{R^{O2}}$ representerer hydrogen eller (C_{1-4})alkyl;

• eller $\mathbf{Ar^1}$ representerer 8- til 10-leddet delvis aromatisk fusjonert bisyklisk heterosyklyl omfattende ett til fire heteroatomer uavhengig valgt fra nitrogen, oksygen og svovel; hvori det 8- til 10-leddede heterosyklylet er koblet til resten av molekylet ved den aromatiske ringdelen; hvori det 8- til 10-leddede heterosyklylet uavhengig er usubstituert, mono- eller disubstituert, hvori substituentene uavhengig velges fra okso, (C_{1-6})alkyl og -(C_{0-3})alkylen-COO$\mathbf{R^{O3}}$ hvori $\mathbf{R^{O3}}$ representerer hydrogen eller (C_{1-3})alkyl;

2. Forbindelse for kombinasjonsanvendelse ifølge krav 1; hvori i forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, representerer $\mathbf{Ar^1}$

• en fenylgruppe av strukturen (Ar-IV):



(Ar-IV)

hvori

• $\mathbf{R^p}$ representerer;

> (C_{4-6})sykloalkyl som inneholder et ringoksygenatom, hvori (C_{4-6})sykloalkylet som inneholder et ringoksygenatom er usubstituert eller monosubstituert med fluor, hydroksy eller metoksy;

> hydroksy;

> -**X^1**-CO-**R^{O1}**, hvori

> **X^1** representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C=C-, -NH-CO-*, -CO- eller (C_{3-5})sykloalkylen; hvori asteriskene indikerer bindingen som er koblet til -CO-**R^{O1}**-gruppen; og

> **R^{O1}** representerer

▪ -OH;

▪ -O-(C_{1-4})alkyl;

▪ -NH-SO_2-**R^{S3}** hvori **R^{S3}** representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;

▪ -O-CH_2-CO-**R^{O4}**, hvori **R^{O4}** representerer hydroksy eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$;

▪ -O-CH_2-O-CO-**R^{O5}**, hvori **R^{O5}** representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

▪ -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller

▪ (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

> -CO-H;

>



;

➢ 2-hydroksy-3,4-diokso-syklobut-1-enyl;

➢ -N**R^{N1}R^{N2}**, hvori

▪ **R^{N1}** uavhengig representerer hydrogen eller (C_{1-4})alkyl, og **R^{N2}** uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl eller -CO-(C_{1-3})alkylen-OH;

> -CO-N**R^{N3}R^{N4}** hvori **R^{N3}** og **R^{N4}** uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl eller hydroksy;

> -NH-CO-N**R^{N5}R^{N6}** hvori **R^{N5}** og **R^{N6}** uavhengig representerer hydrogen eller (C_{1-4})alkyl;

> 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

> **HET**, hvori **HET** representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede heteroarylet er usubstituert, eller mono- eller disubstituert, hvori substituentene velges uavhengig fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl eller -N**R^{N9}R^{N10}** hvori **R^{N9}** og **R^{N10}** uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• **R^{m1}** representerer

> (C_{1-6})alkyl;

> (C_{1-4})alkoksy;

> (C_{1-3})fluoralkyl;

> (C_{1-3})fluoralkoksy;

> halogen;

> (C_{3-6})sykloalkyl;

> (C_{3-6})sykloalkyl-oksy;

> -N**R^{N1}R^{N2}**, hvori **R^{N1}** og **R^{N2}** uavhengig representerer hydrogen, (C_{1-4})alkyl eller (C_{3-6})sykloalkyl; eller

> -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl eller 2-fluor-vinyl; og

• $\mathbf{R^{m2}}$ representerer hydrogen, fluor eller klor;

• eller $\mathbf{R^{p}}$ representerer hydrogen;

$\mathbf{R^{m1}}$ representerer 1H-pyrazol-1-yl; eller -$\mathbf{X^1}$-COOH, hvori $\mathbf{X^1}$ representerer en direktebinding, (C_{1-3})alkylen eller -O-(C_{1-3})alkylen-*, hvori asteriskene indikerer bindingen som er koblet til -COOH-gruppen;

og $\mathbf{R^{m2}}$ representerer hydrogen, (C_{1-4})alkoksy; eller -S-(C_{1-4})alkyl;

• eller $\mathbf{Ar^1}$ representerer en 5-leddet heteroarylgruppe av strukturen (Ar-II):



(Ar-II)

hvori i (Ar-II) representerer ringen A en tiofenyl- eller en tiazolylring;
hvori

• $\mathbf{R^7}$ representerer

➢ 3-hydroksy-oksetan-3-yl;

➢ hydroksy;

➢ 2,2,2-trifluor-1,1-dihydroksy-etyl;

➢ -$\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, hvori

> $\mathbf{X^1}$ representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C≡C-, -NH-CO-*, -CO- eller (C_{3-5})sykloalkylen; hvori asteriskene indikerer bindingen som er koblet til -CO-$\mathbf{R^{O1}}$-gruppen; og

> $\mathbf{R^{O1}}$ representerer

▪ -OH;

▪ -O-(C_{1-4})alkyl;

▪ -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;

▪ -O-fenyl;

▪ -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$;

▪ -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

▪ -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller

▪ (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

> -CO-CH_2-OH;

> -CO-H;

>



> hydroksy-(C_{1-4})alkyl;

> -N$\mathbf{R^{N1}R^{N2}}$, hvori

▪ $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl eller (C_{3-6})sykloalkyl;

▪ eller $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl, og $\mathbf{R^{N2}}$ uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl eller -CO-(C_{1-3})alkylen-OH;

> -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy, hydroksy-(C_{2-4})alkoksy, benzyloksy eller hydroksy;

> -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

> 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl; eller

> **HET**, hvori **HET** representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede heteroarylet er usubstituert, eller mono- eller disubstituert, hvori substituentene velges uavhengig fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• og $(\mathbf{R^6})_n$ representerer en valgfri substituent uavhengig valgt fra

> (C_{1-6})alkyl;

> (C_{1-4})alkoksy;

> (C_{1-3})fluoralkyl;

> (C_{1-3})fluoralkoksy;

> halogen;

> (C_{3-6})sykloalkyl;

> (C_{3-6})sykloalkyl-oksy;

> hydroksy;

> pyridinyl; og

> -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl eller (C_{3-6})sykloalkyl;

• eller $\mathbf{Ar^1}$ representerer 9- eller 10-leddet bisyklisk heteroaryl; hvori det 9- eller 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono- eller disubstituert, hvori substituentene velges uavhengig fra (C_{1-4})alkyl; (C_{1-4})alkoksy; (C_{1-3})fluoralkyl; (C_{1-3})fluoralkoksy; halogen; cyano; hydroksy eller -(C_{0-3})alkylen-COO$\mathbf{R^{O2}}$ hvori $\mathbf{R^{O2}}$ representerer hydrogen eller (C_{1-4})alkyl;

• eller **Ar[1]** representerer en gruppe av strukturen (Ar-III):



(Ar-III)

hvori ring (B) representerer en ikke-aromatisk 5- eller 6-leddet ring fusjonert til fenylgruppen, hvori ring (B) omfatter ett eller to heteroatomer uavhengig valgt fra nitrogen og oksygen; hvori ringen (B) uavhengig er usubstituert, mono- eller disubstituert, hvori substituentene velges uavhengig fra okso, (C_{1-6})alkyl og -(C_{0-3})alkylen-COO**R^{O3}** hvori **R^{O3}** representerer hydrogen eller (C_{1-3})alkyl.

3. Forbindelse for kombinasjonsanvendelse ifølge krav 1 eller 2; hvori i forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, representerer



-gruppen



hvori

R^{2} representerer metyl, klor eller cyano; og

R^{13} representerer hydrogen; og

• **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** uavhengig representerer det følgende:

R^{14} representerer hydrogen, metyl, etyl, metoksy, brom, klor, fluor, trifluormetyl, trifluormetoksy eller cyano;

R^{15} representerer hydrogen, metyl, metoksy, klor, fluor;

R^{16} representerer hydrogen, metoksy eller fluor; og

R^{17} representerer hydrogen, metyl, metoksy, klor, fluor eller cyano;

hvori minst én av **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** representerer hydrogen;

• eller **R^{14}** og **R^{15}** sammen danner en gruppe -O-CH_2-O-, **R^{16}** representerer hydrogen og **R^{17}** representerer hydrogen eller halogen;
eller

R^{2} representerer (C_{1-3})alkyl, halogen eller cyano; og

R^{13} representerer fluor; og

• **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** uavhengig representerer det følgende:

R^{14} representerer hydrogen, metyl, etyl, metoksy, brom, klor, fluor, trifluormetyl, trifluormetoksy eller cyano;

R^{15} representerer hydrogen, metyl, metoksy, klor, fluor;

R^{16} representerer hydrogen, metoksy eller fluor; og

R^{17} representerer hydrogen, metyl, metoksy, klor, fluor eller cyano;

hvori minst to av **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** representerer hydrogen.

4. Forbindelse for kombinasjonsanvendelse ifølge et hvilket som helst av kravene 1 til 3; hvori i forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, representerer



-gruppen en gruppe valgt fra de følgende gruppene A), B), C), D) og E):

A)





og

B)



og

C)







D)



E)



5. Forbindelse for kombinasjonsanvendelse ifølge krav 1; hvori forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, også er en forbindelse av formel (II), eller et farmasøytisk akseptabelt salt derav,



Formel (II)

hvori

R^2 representerer metyl, klor eller cyano; og

• **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** uavhengig representerer det følgende:

R^{14} representerer metyl, metoksy, halogen eller cyano;

R^{15} representerer hydrogen, metyl, klor eller fluor;

R^{16} representerer hydrogen eller fluor; og

R^{17} representerer hydrogen, klor eller fluor;

hvori minst én av **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** representerer hydrogen

og **Ar^1** representerer

• en fenylgruppe av strukturen (Ar-IV):



(Ar-IV)

hvori

• **R^p** representerer;

> hydroksy;

> -COOH;

> -CO-CH_2-CN;

> -CO-(C_{1-4})alkoksy;

> -CO-NH-SO_2-**R^{S3}** hvori **R^{S3}** representerer **R^{S3}** representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl; (C_{3-6})sykloalkyl-(C_{1-3})alkyl; (C_{1-3})fluoralkyl, fenyl eller -NH_2;

> -**X^1**-CH_2-COOH, hvori **X^1** representerer O eller NH;

> -CO-N$R^{N3}R^{N4}$ hvori R^{N3} og R^{N4} uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy eller hydroksy-(C_{2-4})alkoksy;

> -NH-CO-N$R^{N5}R^{N6}$ hvori R^{N5} og R^{N6} uavhengig representerer hydrogen eller (C_{1-4})alkyl;

> -SO_2-R^{S1} hvori R^{S1} representerer hydroksy, (C_{1-4})alkyl, eller -N$R^{N7}R^{N8}$ hvori R^{N7} og R^{N8} uavhengig representerer hydrogen eller (C_{1-3})alkyl;

> 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl;

> tetrazolyl (spesielt 1H-tetrazol-5-yl); eller

> 5- eller 6-leddet heteroaryl valgt fra oksazolyl, isoksazolyl, oksadiazolyl, tiazolyl, isotiazolyl, tiadiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl eller pyrazinyl; hvori det 5- eller 6-leddede heteroarylet er usubstituert eller mono- eller disubstituert, hvori substituentene velges uavhengig fra (C_{1-3})alkyl, (C_{1-3})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl eller -N$R^{N9}R^{N10}$ hvori R^{N9} og R^{N10} uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• R^{m1} representerer

> hydrogen;

> (C_{1-6})alkyl;

> (C_{1-4})alkoksy;

> (C_{1-3})fluoralkyl;

> (C_{1-3})fluoralkoksy;

> halogen;

> (C_{3-6})sykloalkyl;

> (C_{3-6})sykloalkyl-oksy;

> hydroksy;

> -$(CH_2)_m$-N$R^{N1}R^{N2}$, hvori **m** representerer heltallet 0 eller 1; og hvori R^{N1} og R^{N2} uavhengig representerer hydrogen, (C_{1-3})alkyl eller (C_{2-3})fluoralkyl; eller R^{N1} og R^{N2} sammen med nitrogenet som de er festet til danner en pyrrolidinylring; eller

> -S-R^{S2} hvori R^{S2} representerer (C_{1-4})alkyl eller (C_{3-6})sykloalkyl;

• og R^{m2} representerer

> hydrogen; eller

> (C_{1-6})alkyl;

➢ (C_{1-3})alkoksy; eller

➢ halogen;

• eller Ar^1 representerer en 5-leddet heteroarylgruppe av strukturen (Ar-V):



(Ar-V)

hvori i (Ar-V) representerer ringen A en tiofenyl- eller en tiazolylring;

hvori R^{A1} representerer

> -COOH;

> tetrazolyl;

> -CO-(C_{1-4})alkoksy;

> -CO-NH-SO_2-R^{S3} hvori R^{S3} representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl; (C_{3-6})sykloalkyl-(C_{1-3})alkyl; (C_{1-3})fluoralkyl, fenyl eller -NH_2;

> -X^1-CH_2-COOH, hvori X^1 representerer O eller NH; eller

> -CO-N$R^{N3}R^{N4}$ hvori R^{N3} og R^{N4} uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl eller (C_{1-3})alkoksy-(C_{2-4})alkyl;

og R^{A2} representerer

> hydrogen;

> (C_{1-6})alkyl;

> (C_{1-4})alkoksy;

> (C_{1-3})fluoralkyl;

> halogen; eller

> hydroksy;

• eller Ar^1 representerer 9- eller 10-leddet bisyklisk heteroaryl valgt fra 1H-indol-5-yl, 1H-indol-4-yl, 1H-indol-6-yl, indazol-6-yl, 1H-benzoimidazol-5-yl, 1H-benzotriazol-5-yl, kinoksalin-6-yl, isokinolin-7-yl og kinolin-6-yl; hvori det 9- eller 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono- eller disubstituert, hvori substituentene velges uavhengig fra (C_{1-4})alkyl eller -COOH;

• eller Ar^1 representerer en gruppe av strukturen (Ar-III):



(Ar-III)

hvori ring (B) representerer en ikke-aromatisk 5-leddet ring fusjonert til fenylgruppen, hvori ring (B) omfatter ett eller to nitrogenringatomer; hvori ringen (B) uavhengig er usubstituert, mono- eller disubstituert, hvori substituentene uavhengig velges fra okso og (C_{1-6})alkyl.

6. Forbindelse for kombinasjonsanvendelse ifølge krav 1; hvori i forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, er det også en

forbindelse av formel (III), eller et farmasøytisk akseptabelt salt derav:



Formel (III)

hvori gruppen:



representerer en gruppe valgt fra de følgende gruppene A), B), C), D) og E):

A)



og

;

B)



og

;

C)

 og  ;

D)

 ;

E)





 og ;

og

Ar^{1} representerer

• fenyl, eller 5-leddet heteroaryl valgt fra tiofenyl og tiazolyl; hvori fenylet eller det 5-leddede heteroarylet uavhengig er mono-, di- eller trisubstituert;

hvori én av substituentene velges fra

• -**X^{1}**-CO-**R^{O1}**, hvori

▪ **X^{1}** representerer en direktebinding, -CH_2-CH_2-, -O-CH_2-*, -NH-CH_2-*, -CH=CH- eller -NH-CO-*; hvori asteriskene indikerer bindingen som er koblet til -CO-**R^{O1}**-gruppen; og

▪ **R^{O1}** representerer

• -OH;

• -O-(C_{1-4})alkyl;

• -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-3})alkyl, syklopropyl eller -NH_2;

• -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy eller (C_{1-4})alkoksy; eller

• -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

• -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl, og $\mathbf{R^{N2}}$ representerer -CO-H;

• 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

• 1H-tetrazol-5-yl;

• 3-hydroksy-isoksazol-5-yl;

• imidazolyl, som er usubstituert, eller mono- eller disubstituert med metyl;

• pyrazolyl;

• isoksazolyl, oksazolyl, eller tiadiazolyl; hvori isoksazolylet, oksazolylet eller tiadiazolylet er monosubstituert med -N$\mathbf{R^{N9}R^{N10}}$, hvori $\mathbf{R^{N9}}$ representerer hydrogen, og $\mathbf{R^{N10}}$ representerer hydrogen eller metyl;

og den gjenværende én eller to av substituentene (hvis til stede) velges uavhengig fra

• (C_{1-4})alkyl;

• (C_{1-4})alkoksy;

• 2,2,2-trifluoretoksy;

• halogen;

• -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ representerer hydrogen, og $\mathbf{R^{N2}}$ representerer (C_{1-3})alkyl;

• -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl;

• eller **Ar^{1}** representerer 8- til 10-leddet bisyklisk heteroaryl valgt fra usubstituert benzimidazol; usubstituert indazolyl, og indolyl som er usubstituert eller monosubstituert med -COO**R^{O2}** hvori **R^{O2}** representerer hydrogen eller (C_{1-4})alkyl;

• eller **Ar^{1}** representerer oksosubstituert 8- til 10-leddet delvis aromatisk fusjonert bisyklisk heterosyklyl valgt fra 2-okso-2,3-dihydro-benzooksazolyl, 3-okso-2,3-dihydro-1H-indazolyl, 2-okso-1,2,3,4-tetrahydro-kinazolinyl, 1-okso-1,2,3,4-tetrahydro-isokinolinyl; hvori det oksosubstituerte heterosyklylet er usubstituert eller monosubstituert på et ringnitrogenatom med (C_{1-3})alkyl.

7. Forbindelse for kombinasjonsanvendelse ifølge krav 1; hvori forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, velges fra gruppen som består av:

3-klor-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl]-3-etoksy-tiofen-2-karboksylsyre;

[6-(2,3-dihydro-1H-indol-5-yl)-pyrimidin-4-yl]-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

3-etyl-5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-metyl-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-etyl-5-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-klor-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

5-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

{6-[4-(3-amino-isoksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2H-pyrazol-3-yl)-fenyl]-pyrimidin-4-yl}-amin;

3-etoksy-5-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(6-klor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(7-fluor-2,5-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etyl-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(4,6-diklor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-6-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-7-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-6-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

5-{6-[2-(7-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(4,6,7-trifluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(4,5,7-trifluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(6,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

{6-[4-(3-amino-isoksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

5-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

2-etylamino-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

5-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

4-(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-2-karboksylsyre;

2-klor-4-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-klor-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

5-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

1-etyl-3-(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-urea;

{6-[4-(2-amino-oksazol-5-yl)-fenyl]-pyrimidin-4-yl]-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

{6-[4-(2-amino-oksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

2-(4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-4-karboksylsyre;

2-(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-4-karboksylsyre;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propoksy-benzosyre;

2-butoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

{6-[4-(2-amino-oksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

{6-[3-etoksy-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(7-klor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-amin;

{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl]-[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

3-butoksy-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-butoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-propoksy-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-propoksy-tiofen-2-karboksylsyre;

3-(4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-4H-[1,2,4]oksadiazol-5-on;

2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-isobutoksy-benzosyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

6-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1,2-dihydro-indazol-3-on;

4-{6-[2-(2-klor-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

5-{6-[2-(2-klor-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(4-brom-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[5-(1H-tetrazol-5-yl)-tiofen-2-yl]-pyrimidin-4-yl}-amin;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-hydroksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

1-(2-{6-[3-etoksy-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

N-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl]-3-etoksy-tiofen-2-karbonyl)-metansulfonamid;

(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenoksy)-eddiksyre;

(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-eddiksyre;

5-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

N-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-benzensulfonamid;

Propane-2-sulfonsyre-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-amid;

Syklopropansulfonsyre-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-amid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyremetylamid;

Etansulfonsyre-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-amid;

7-fluor-1-(2-{6-[4-(1H-imidazol-4-yl)-3-metoksy-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-(2-{6-[4-(5-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-1H-indol-2-karbonitril;

1-(2-{6-[3-etoksy-4-((5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(2,5-dimetyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(3-etyl-4-hydroksy-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(1,5-dimetyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(1,2-dimetyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-(2-{6-[4-((5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-(2-{6-[5-(3-hydroksy-oksetan-3-yl)-4-metoksy-tiofen-2-yl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(2-syklopropyl-1-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-trifluormetoksy-fenoksy)-eddiksyre;

7-fluor-1-(2-{6-[4-(3H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

3-(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-[1,2,4]oksadiazol-5(4H)-on;

7-fluor-1-(2-{6-[4-(3-okso-2,3-dihydro-1,2,4-oksadiazol-5-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-(2,2,2-trifluor-etoksy)-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etyl-fenoksy)-eddiksyre;

3-(2-etoksy-4-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-[1,2,4]oksadiazol-5(4H)-on;

2-butoksy-6-klor-4-(6-((2-(7-fluor-4-metoksy-2-metyl-1H-indol-1-yl)etyl-1,1,2,2-d4)amino)pyrimidin-4-yl)benzosyre;

5-{6-[2-(7-klor-5-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl]-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-(2,2,2-trifluor-etoksy)-tiofen-2-karboksylsyre;

2-(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-propionsyre;

5-{6-[2-(2-cyano-3-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

7-fluor-1-(2-{6-[4-(3-hydroksy-isoksazol-5-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

N-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenyl)-oksalamsyre;

7-fluor-1-(2-{6-[4-(3-hydroksy-isoksazol-5-yl)-3-metoksy-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

1-(2-{6-[4-(2-syklopropyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(6-klor-7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

7-fluor-1-{2-[6-(4-hydroksy-3-trifluormetoksy-fenyl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(3-klor-4-hydroksy-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(4,6-diklor-7-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

5-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

2-butoksy-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-trifluormetoksy-fenol;

3-etoksy-5-{6-[2-(3-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-3-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(2-etoksy-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-eddiksyre;

2-butoksy-4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

5-{6-[2-(2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-(2-etoksy-4-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-[1,2,4]oksadiazol-5(4H)-on;

5-{6-[2-(4,6-diklor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-5,6-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

(4-{6-[2-(2-cyano-7-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

1-{2-[6-(3-etoksy-4-hydroksy-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyreamid;

5-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

2-butoksy-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-fluor-benzosyre;

2-butoksy-6-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

2-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propoksy-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-6-propoksy-benzosyre;

5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

2-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-isobutoksy-benzosyre;

(4-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

(4-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-difluormetoksy-benzosyre;

7-fluor-4-metoksy-1-{2-[6-(1-metyl-2-okso-1,2,3,4-tetrahydro-kinazolin-7-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1-metyl-3-okso-2,3-dihydro-1H-indazol-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-etylsulfanyl-benzosyre;

7-fluor-4-metoksy-1-(2-{6-[4-(3H-[1,2,3]triazol-4-yl)-fenyl]-pyrimidin-4-ylamino]-etyl)-1H-indol-2-karbonitril;

3-(3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-etoksy-fenoksy)-propionsyre;

3-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-propionsyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-3-fluor-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzensulfonamid;

1-(2-{6-[3-etoksy-4-(3H-[1,2,3]triazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

3-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-yl)-propionsyre;

7-fluor-1-(2-{6-[4-(2-hydroksy-3,4-diokso-syklobut-1-enyl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenyl)-okso-eddiksyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isopropylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isopropylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-6-propyl-benzosyre;

5-{6-[2-(2-cyano-5,7-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-6,7-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl]-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

(4-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutoksy-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propoksy-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6,7-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

2-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1H-indol-5-karboksylsyre;

7-fluor-1-{2-[6-(1H-indol-2-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

2-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1H-indol-5-karboksylsyremetylester;

7-fluor-1-(2-{6-[4-(2-hydroksy-etoksy)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1H-indol-6-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1H-pyrrolo[2,3-c]pyridin-3-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1H-indol-3-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(2-okso-1,2,3,4-tetrahydro-kinazolin-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

N-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-formamid;

7-fluor-4-metoksy-1-{2-[6-(2-okso-2,3-dihydro-benzooksazol-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(3-metyl-2-okso-2,3-dihydro-benzooksazol-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1-metyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

1-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-3-etyl-urea;

1-{2-[6-(1H-benzoimidazol-5-yl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(3H-benzotriazol-5-yl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1-okso-1,2,3,4-tetrahydro-isokinolin-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

1-{2-[6-(3-etoksy-4-formyl-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1H-indol-5-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-benzosyremetylester;

7-fluor-1-{2-[6-(4-hydroksy-3-trifluormetyl-fenyl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-etoksy-benzosyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-3-karboksylsyreetylester;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

4-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

3-(5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-yl)-propionsyre;

3-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-propionsyre;

(E)-3-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-akrylsyre;

4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

3-klor-5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-klor-5-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karbonyl)-metansulfonamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyreetylamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyredimetylamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-(2-hydroksy-etyl)-amid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyreisopropylamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-(2-metoksy-etyl)-amid;

5-(6-((2-(2-cyano-7-fluor-4-metoksy-1H-indol-1-yl)etyl)amino)pyrimidin-4-yl)-3-etoksy-N-sulfamoyltiofen-2-karboksamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrehydroksyamid;

(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-metanol;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-isopropoksy-tiazol-5-karboksylsyre;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-metoksy-tiazol-5-karboksylsyre;

4-etoksy-2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiazol-5-karboksylsyre;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-propoksy-tiazol-5-karboksylsyre;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-isobutyl-tiazol-5-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrekarboksymetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyredimetylkarbamoylmetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrebutyryloksymetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyreetoksykarbonyloksymetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-5-metyl-2-okso-[1,3]dioksol-4-ylmetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-2-dimetylamino-etylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrefenylester;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-propynoinsyreetylester;

{6-[4-etoksy-5-(1H-tetrazol-5-yl)-tiofen-2-yl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-N-hydroksy-tiofen-2-karboksamidin;

3-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-[1,2,4]oksadiazol-5(4H)-on;

5-{6-[2-(3,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[5-(2H-tetrazol-5-yl)-4-trifluormetyl-tiofen-2-yl]-pyrimidin-4-yl}-amin;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-N-hydroksy-3-trifluormetyl-tiofen-2-karboksamidin;

3-(5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-yl)-[1,2,4]oksadiazol-5(4H)-on;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-N-hydroksy-benzamid;

5-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-isoksazol-3-ol;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-pyridin-2-yl-tiofen-2-karboksylsyre;

[6-(4-etylamino-tiofen-2-yl)-pyrimidin-4-yl]-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

[6-(4-etylamino-tiofen-2-yl)-pyrimidin-4-yl]-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

[6-(4-etylamino-tiofen-2-yl)-pyrimidin-4-yl]-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

N-etyl-N-(5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-3-yl)-formamid;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-formamid;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-propionamid;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-3-hydroksy-propionamid;

(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-urea; og

5-{6-[2-(2-cyano-3,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

eller et farmasøytisk akseptabelt salt derav.

8. Forbindelse for kombinasjonsanvendelse ifølge krav 1; hvori i forbindelsen av formel (I), eller det farmasøytisk akseptable saltet derav, er 4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre, eller et farmasøytisk akseptabelt salt derav.

9. Forbindelse for kombinasjonsanvendelse ifølge et hvilket som helst av kravene 1 til 8; hvori kreften velges fra melanom; lungekreft; blærekreft; nyrekarsinomer; kreft i mage-tarmkanalen; endometriekreft; eggstokkreft; livmorhalskreft; og nevroblastom.

10. Forbindelse for kombinasjonsanvendelse ifølge et hvilket som helst av kravene 1 til 9; hvori forbindelsen anvendes i kombinasjon med ett eller flere kjemoterapimidler uavhengig valgt fra:

a) alkyleringsmidler;

b) platinalegemidler;

c) antimetabolittlegemidler;

d) anti-tumorantibiotika;

e) mitotiske inhibitorer; og

f) topoisomeraseinhibitorer.

11. Forbindelse for kombinasjonsanvendelse ifølge krav 1 eller 10; hvori det ene eller flere kjemoterapimidlene velges uavhengig fra:

a) alkyleringsmidler valgt fra mekloretamin, klorambucil, syklofosfamid, ifosfamid, streptozocin, karmustin, lomustin, melfalan, dakarbazin, temozolomid, fotemustin, tiotepa og altretamin;

b) platinalegemidler valgt fra cisplatin, karboplatin og oksaliplatin;

c) antimetabolittlegemidler valgt fra 5-fluoruracil, folsyre/leukovorin, capecitabin, 6-merkaptopurin, metotreksat, gemcitabin, cytarabin, fludarabin eller pemetreksed; spesielt 5-fluoruracil, folsyre/leukovorin, capecitabin, metotreksat, gemcitabin og pemetreksed;

d) anti-tumorantibiotika valgt fra daunorubicin, doksorubicin, epirubicin, idarubicin, aktinomycin-D, bleomycin, mitomycin-C. og mitoksantron;

e) mitotiske inhibitorer valgt fra paklitaksel, docetaksel, iksabepilon, vinblastin, vinkristin, vinorelbin, vindesin og estramustin; og

f) topoisomeraseinhibitorer valgt fra etoposid, teniposid, topotekan, irinotekan, diflomotekan og elomotekan.

12. Forbindelse for kombinasjonsanvendelse ifølge et hvilket som helst av kravene 1 til 9; hvori forbindelsen anvendes i kombinasjon med stråleterapi.

13. Forbindelse for kombinasjonsanvendelse ifølge et hvilket som helst av kravene 1 til 9; hvori forbindelsen anvendes i kombinasjon med én eller flere målrettede terapier.

14. Forbindelse for kombinasjonsanvendelse ifølge krav 1 til 9, eller 13; hvori den målrettede terapien velges uavhengig fra:

a) Inhibitorer av epidermal vekstfaktorreseptor (EGFR) eller blokkerende antistoffer;

b) RAS/RAF/MEK-signalveiinhibitorer;

c) Aromataseinhibitorer;

d) Angiogeneseinhibitorer;

e) Immunsjekkpunktinhibitorer;

f) Vaksinasjonstilnærminger valgt fra: dendrittisk cellevaksinasjon og peptid- eller proteinvaksinasjon;

g) Gjeninnføring av pasientutledede eller allogene (ikke-selv) kreftceller genetisk modifisert for å utskille immunmodulerende faktorer;

h) T-cellebaserte adoptive immunterapier;

i) Cytokin- eller immuncytokinbasert terapi;

j) Agonister av toll-lignende reseptor (TLR);

k) Talidomidanaloger (for eksempel Lenalidomid, Pomalidomid);

l) Inhibitorer av indolamin-2,3-dioksygenase (IDO) og/eller tryptofan-2,3-dioksygenase (TDO);

m) Aktivatorer av T-celle-kostimulerende reseptorer;

n) Molekyler som binder et tumorspesifikt antigen så vel som en T-celleoverflatemarkør;

o) Antistoffer eller inhibitorer med liten molekylvekt som målrettes mot kolonistimulerende faktor-1-reseptor (CSF-1R);

p) Midler som målrettes mot immuncellesjekkpunkter på naturlige dreperceller; og

q) Midler som målrettes mot adenosinreseptorene eller ektonukleasene CD39 og CD73 som omdanner ATP til adenosin.

15. Forbindelse for kombinasjonsanvendelse ifølge krav 1 til 9, eller 13; hvori den målrettede terapien velges uavhengig fra:

a) Inhibitorer av epidermal vekstfaktorreseptor (EGFR) eller blokkerende antistoffer valgt fra: Gefitinib, Erlotinib, Afatinib, Ikotinib, Lapatinib, Panitumumab, Zalutumumab, Nimotuzumab, Matuzumab og Cetuksimab;

b) RAS/RAF/MEK- signalveiinhibitorer valgt fra: Vemurafenib, Sorafenib, Dabrafenib, GDC-0879, PLX-4720, LGX818, RG7304, Trametinib, Cobimetinib, Binimetinib og Selumetinib;

c) Aromataseinhibitorer valgt fra: Eksemestan, Letrozol, Anastrozol, Vorozol, Formestan og Fadrozol;

d) Angiogeneseinhibitorer valgt fra: Bevacuzimab, Ramucirumab, Sorafenib og Aksitinib;

e) Immunsjekkpunktinhibitorer valgt fra: Pembrolizumab, Nivolumab, Pidilizumab, AMP-514, PDR001, SHR-1210, REGN2810, BGBA317, AMP-224; BMS-936559, atezolizumab, MEDI4736, avelumab, durvalumab, ipilimumab, tremilmumab, BMS-986016, IMP701, MK-4280, ImmuFact IMP321, MBG453, urelumab, PF-05082566 og RG6058;

f) Vaksinasjonstilnærminger med gp100-peptid eller MAGE-A3-peptid;

g) Gjeninnføring av pasientutledede eller allogene (ikke-selv) kreftceller genetisk modifisert for å utskille immunmodulerende faktorer valgt fra: granulocyttmonocyttkolonistimulerende faktor (GMCSF) gentransfektert tumorcellevaksine (GVAX) eller Fms-relatert tyrosinkinase 3 (Flt-3) ligandgentransfektert tumorcellevaksine (FVAX), og toll-lignende reseptorforsterket GM-CSF-tumorbasert vaksine (TEGVAX);

h) T-cellebasert adoptiv immunterapi som er CTL019;

i) Cytokin- eller immuncytokinbasert terapi valgt fra: interferon alfa, interferon beta, interferon gamma, interleukin 2 og interleukin 15;

j) Agonister av toll-lignende reseptor (TLR) valgt fra: resiquimod, imiquimod, glukopyranosyllipid A og CpG-oligodesoksynukleotider;

k) talidomidanaloger valgt fra: Lenalidomid og Pomalidomid;

l) Inhibitorer av indolamin-2,3-dioksygenase (IDO) og/eller tryptofan-2,3-dioksygenase (TDO) valgt fra: RG6078, indoksimod, epakadostat, PF-06840003 og F001287;

m) Aktivatorer av T-celle-kostimulerende reseptorer valgt fra: RG7888, 9B12, MEDI6469, GSK3174998, MEDI0562, TRX518, MEDI1873, MK-4166, BMS-986156, Dacetuzumab, HCD122, CP-870,893, RG7876, ADC-1013, APX005M, SEA-CD40; BG9588 og Varlilumab;

n) Molekyler som binder et tumorspesifikt antigen så vel som en T-celleoverflatemarkør valgt fra: AMG103 og AMG330;

o) Antistoffer eller inhibitorer med liten molekylvekt som målrettes mot kolonistimulerende faktor-1-reseptor (CSF-1R) valgt fra: Emactuzumab, Cabiralizumab og PLX3397;

p) Midler som målrettes mot immuncellesjekkpunkter på naturlige dreperceller som er Lirilumab; og

q) Midler som målrettes mot adenosinreseptorene eller ektonukleasene CD39 og CD73 som omdanner ATP til adenosin valgt fra: MEDI9447, PBF-509 og CPI-444.